Literature DB >> 27291491

Photooxygenation of an amino-thienopyridone yields a more potent PTP4A3 inhibitor.

Joseph M Salamoun1, Kelley E McQueeney2, Kalyani Patil1, Steven J Geib1, Elizabeth R Sharlow2, John S Lazo2, Peter Wipf1.   

Abstract

The phosphatase PTP4A3 is an attractive anticancer target, but knowledge of its exact role in cells remains incomplete. A potent, structurally novel inhibitor of the PTP4A family was obtained by photooxygenation of a less active, electron-rich thienopyridone (1). Iminothienopyridinedione 13 displays increased solution stability and is readily obtained by two new synthetic routes that converge in the preparation of 1. The late-stage photooxygenation of 1 to give 13 in high yield highlights the potential of this reaction to modify the structure and properties of a biological lead compound and generate value for expanding the scope of an SAR investigation. Analog 13 should become a valuable tool for further exploration of the role of PTP4A3 in tumor progression.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27291491      PMCID: PMC4935606          DOI: 10.1039/c6ob00946h

Source DB:  PubMed          Journal:  Org Biomol Chem        ISSN: 1477-0520            Impact factor:   3.876


  35 in total

1.  Privileged scaffolds or promiscuous binders: a comparative study on rhodanines and related heterocycles in medicinal chemistry.

Authors:  Thomas Mendgen; Christian Steuer; Christian D Klein
Journal:  J Med Chem       Date:  2012-01-11       Impact factor: 7.446

2.  PRL-3 down-regulates PTEN expression and signals through PI3K to promote epithelial-mesenchymal transition.

Authors:  Haihe Wang; Samantha Yiling Quah; Jing Ming Dong; Edward Manser; Jing Ping Tang; Qi Zeng
Journal:  Cancer Res       Date:  2007-04-01       Impact factor: 12.701

Review 3.  Advancing Biological Understanding and Therapeutics Discovery with Small-Molecule Probes.

Authors:  Stuart L Schreiber; Joanne D Kotz; Min Li; Jeffrey Aubé; Christopher P Austin; John C Reed; Hugh Rosen; E Lucile White; Larry A Sklar; Craig W Lindsley; Benjamin R Alexander; Joshua A Bittker; Paul A Clemons; Andrea de Souza; Michael A Foley; Michelle Palmer; Alykhan F Shamji; Mathias J Wawer; Owen McManus; Meng Wu; Beiyan Zou; Haibo Yu; Jennifer E Golden; Frank J Schoenen; Anton Simeonov; Ajit Jadhav; Michael R Jackson; Anthony B Pinkerton; Thomas D Y Chung; Patrick R Griffin; Benjamin F Cravatt; Peter S Hodder; William R Roush; Edward Roberts; Dong-Hoon Chung; Colleen B Jonsson; James W Noah; William E Severson; Subramaniam Ananthan; Bruce Edwards; Tudor I Oprea; P Jeffrey Conn; Corey R Hopkins; Michael R Wood; Shaun R Stauffer; Kyle A Emmitte
Journal:  Cell       Date:  2015-06-04       Impact factor: 41.582

Review 4.  Challenges and opportunities in the development of protein phosphatase-directed therapeutics.

Authors:  Sofie De Munter; Maja Köhn; Mathieu Bollen
Journal:  ACS Chem Biol       Date:  2012-12-20       Impact factor: 5.100

5.  Identification of 2-(4-pyridyl)thienopyridinones as GSK-3β inhibitors.

Authors:  Gabriella Gentile; Giovanni Bernasconi; Alfonso Pozzan; Giancarlo Merlo; Paola Marzorati; Paul Bamborough; Benjamin Bax; Angela Bridges; Caroline Brough; Paul Carter; Geoffrey Cutler; Margarete Neu; Mia Takada
Journal:  Bioorg Med Chem Lett       Date:  2011-06-29       Impact factor: 2.823

Review 6.  Inhibitors of protein tyrosine phosphatases: next-generation drugs?

Authors:  Laurent Bialy; Herbert Waldmann
Journal:  Angew Chem Int Ed Engl       Date:  2005-06-20       Impact factor: 15.336

Review 7.  PRL-3, an emerging marker of carcinogenesis, is strongly associated with poor prognosis.

Authors:  Katarzyna Guzińska-Ustymowicz; Anna Pryczynicz
Journal:  Anticancer Agents Med Chem       Date:  2011-01       Impact factor: 2.505

Review 8.  A historical overview of protein kinases and their targeted small molecule inhibitors.

Authors:  Robert Roskoski
Journal:  Pharmacol Res       Date:  2015-07-21       Impact factor: 7.658

Review 9.  Phosphatases as targets for cancer treatment.

Authors:  John S Lazo; Peter Wipf
Journal:  Curr Opin Investig Drugs       Date:  2009-12

10.  Rhodanine-based PRL-3 inhibitors blocked the migration and invasion of metastatic cancer cells.

Authors:  Garam Min; Su-Kyung Lee; Hye-Nan Kim; Young-Min Han; Rhan-Hee Lee; Dae Gwin Jeong; Dong Cho Han; Byoung-Mog Kwon
Journal:  Bioorg Med Chem Lett       Date:  2013-05-09       Impact factor: 2.823

View more
  16 in total

1.  Mechanism of thienopyridone and iminothienopyridinedione inhibition of protein phosphatases.

Authors:  Zhidian Zhang; Guennadi Kozlov; Yu Seby Chen; Kalle Gehring
Journal:  Medchemcomm       Date:  2019-04-05       Impact factor: 3.597

2.  Next-Generation Cell-Active Inhibitors of the Undrugged Oncogenic PTP4A3 Phosphatase.

Authors:  John S Lazo; Isabella K Blanco; Nikhil R Tasker; Ettore J Rastelli; James C Burnett; Sharon R Garrott; Duncan J Hart; Rebecca L McCloud; Ku-Lung Hsu; Peter Wipf; Elizabeth R Sharlow
Journal:  J Pharmacol Exp Ther       Date:  2019-10-10       Impact factor: 4.030

3.  PRL3 pseudophosphatase activity is necessary and sufficient to promote metastatic growth.

Authors:  Guennadi Kozlov; Yosuke Funato; Yu Seby Chen; Zhidian Zhang; Katalin Illes; Hiroaki Miki; Kalle Gehring
Journal:  J Biol Chem       Date:  2020-06-22       Impact factor: 5.157

Review 4.  Therapeutic Targeting of Oncogenic Tyrosine Phosphatases.

Authors:  Rochelle Frankson; Zhi-Hong Yu; Yunpeng Bai; Qinglin Li; Ruo-Yu Zhang; Zhong-Yin Zhang
Journal:  Cancer Res       Date:  2017-08-30       Impact factor: 12.701

5.  Structure of the Complex of an Iminopyridinedione Protein Tyrosine Phosphatase 4A3 Phosphatase Inhibitor with Human Serum Albumin.

Authors:  Mateusz P Czub; Adam M Boulton; Ettore J Rastelli; Nikhil R Tasker; Taber S Maskrey; Isabella K Blanco; Kelley E McQueeney; John H Bushweller; Wladek Minor; Peter Wipf; Elizabeth R Sharlow; John S Lazo
Journal:  Mol Pharmacol       Date:  2020-09-25       Impact factor: 4.436

Review 6.  The Curtius Rearrangement: Applications in Modern Drug Discovery and Medicinal Chemistry.

Authors:  Arun K Ghosh; Margherita Brindisi; Anindya Sarkar
Journal:  ChemMedChem       Date:  2018-10-11       Impact factor: 3.466

7.  A chemical genetics approach identifies PTP4A3 as a regulator of colon cancer cell adhesion.

Authors:  Kelley E McQueeney; Joseph M Salamoun; Jennifer G Ahn; Paula Pekic; Isabella K Blanco; Heather L Struckman; Elizabeth R Sharlow; Peter Wipf; John S Lazo
Journal:  FASEB J       Date:  2018-05-10       Impact factor: 5.191

8.  Synthesis and evaluation of bifunctional PTP4A3 phosphatase inhibitors activating the ER stress pathway.

Authors:  Ettore J Rastelli; Sara Sannino; Duncan J Hart; Elizabeth R Sharlow; John S Lazo; Jeffrey L Brodsky; Peter Wipf
Journal:  Bioorg Med Chem Lett       Date:  2021-06-02       Impact factor: 2.940

9.  Expression of phosphatase of regenerating liver (PRL)-3, is independently associated with biochemical failure, clinical failure and death in prostate cancer.

Authors:  Sigve Andersen; Elin Richardsen; Mehrdad Rakaee; Helena Bertilsson; Roy Bremnes; Magne Børset; Lill-Tove Busund; Tobias Slørdahl
Journal:  PLoS One       Date:  2017-11-30       Impact factor: 3.240

Review 10.  Critical Roles of Dual-Specificity Phosphatases in Neuronal Proteostasis and Neurological Diseases.

Authors:  Noopur Bhore; Bo-Jeng Wang; Yun-Wen Chen; Yung-Feng Liao
Journal:  Int J Mol Sci       Date:  2017-09-13       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.